WuXi XDC, a premier contract research, development, and manufacturing organization (CRDMO) based in China and specializing in the ADC and bioconjugate sector, has adopted an advanced labeling solution from Schreiner MediPharm to support clinical trials for a novel antibody drug conjugate (ADC). Designed to protect light-sensitive active ingredients while securely blinding the drug, Schreiner MediPharm’s Light-Protect-Label addresses the unique challenges of ADC formulations.
In the ongoing clinical trial, the light-sensitive ADC ingredient is stored in vials as a lyophilized powder that must be shielded from external light sources. To meet this requirement, WuXi XDC chose Schreiner MediPharm’s Light-Protect-Label, which not only provides robust light protection but also includes a resealable inspection window, allowing an unaltered view of the drug’s condition. This feature ensures accurate assessment of the lyophilizate’s color and state, crucial for confirming medication efficacy prior to administration.
Schreiner MediPharm customized this innovative solution, leveraging their deep knowledge in material science, adhesive technology, and light-protection testing. The label’s opaque, UV-resistant design fully encloses the vial, optimizing light protection while supporting the clinical trial’s operational efficiency and maintaining patient safety.
This forward-looking label solution aligns well with ADC therapies, which have revolutionized cancer treatment by targeting drugs directly to tumor cells, thereby sparing healthy tissue and minimizing side effects. WuXi XDC’s collaboration with Schreiner MediPharm marks a significant step toward ensuring secure, reliable ADC trials that contribute to the advancement of safer and more effective cancer treatments.
